Jim Cramer says science and technology are responsible for this market strength and we might be seeing the end of the healthcare recession.

Jim Cramer says stocks are oversold, and insiders are buying -- that should give investors hope.

Several Dexcom analysts raised their share-price targets for the diabetes-treatment company after its fourth-quarter earnings beat Wall Street's estimates.

From strong balance sheets to a strong economy, buyers have lots of good reasons to swoop in for the bargains, Jim Cramer says.

Jim Cramer ticks off all the good news for the stock market, from tariffs and earnings to energy and technology.

U.S. stock futures rise as sentiment receives a boost from a stronger-than-expected U.S. jobs report and signs of progress in U.S.-China trade talks; McDonald's fires CEO Steve Easterbrook; Under Armour confirms it's being investigated by federal authorities over its accounting practices; Uber reports earnings.

Jim Cramer says investors are frustrated and confused by this market action. He reviews some of the craziness and explains why it's really reasonable.

Despite some downbeat stories and IPO overhang, Jim Cramer says, we're seeing the market rally thanks to the action in some great individual stocks.

Jim Cramer takes a look at Merck, Cloudflare, Exelon, Advanced Micro Devices, Endo Pharmaceuticals, Ionis Pharmaceuticals, Tandem Diabetes Care and more.

The online retail giant had a plan to own your living room. It didn't work because AI-powered voice assistants don't work.

Online scams are more widespread than ever. Here's how to avoid them.

Tesla's competitors have made progress in cutting the EV leader's market share.